Innovative Approaches in the Management of Advanced Renal Cell Carcinoma (RCC): Managed Care Considerations on Targeted Therapy and Immunotherapy Combinations

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 1, 2023 to March 1, 2024

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. In 2022, it is estimated that there will be approximately 76,080 new cases of kidney cancer, and about 13,780 people will die from the disease. Approximately 16% of patients with RCC will have metastases at diagnosis, and as many as 40% will demonstrate metastasis after primary surgical treatment for localized RCC. With a 5-year survival rate ranging from 5% to 12%, the prognosis for these patients is poor. Fortunately for patients with advanced RCC, several new treatments, including targeted therapies and immunotherapies, have recently become available giving clinicians new options to improve patient outcomes and quality of life. Additionally, new combination regimens comprised of multiple receptor tyrosine kinase inhibitors and anti-PD-1 immunotherapies have shown improved efficacy and safety in clinical trials. With so many new options becoming available for the healthcare community, clinicians are struggling to stay abreast of all the changes in advanced RCC treatment. It is critical that medical directors, oncologists, nurses and other healthcare professionals are updated on these emerging options and strategies for implementing them into the treatment paradigm, which will ultimately improve patient outcomes.

Upon completion of this activity, participants will be able to:

  • Assess the clinical and economic burden of renal cell carcinoma (RCC), including factors that contribute to poor prognosis and increased costs

  • Explain considerations for selecting a first-line treatment regimen for a patient with advanced RCC, including biomarkers, adverse events, and medical comorbidities

  • Analyze the evolving role of TKI and immunotherapy combinations in the first-line management of advanced RCC

  • Identify patients with advanced RCC who might benefit from treatment with TKI and immunotherapy combinations based on current evidence and guideline updates

  • Discuss modifications for drug therapy for toxicity management in patients receiving treatment for advanced RCC with an TKI and immunotherapy combination based on expert recommendations

  • Evaluate the managed care considerations of current and emerging TKI and immunotherapy combinations by exploring where these agents fit in the current RCC management paradigm


Faculty: Neeraj Agarwal, MD
Professor of Medicine
Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Neeraj Agarwal, MD has served as a consultant for Aveo, Exelixis, Genentech, Gilead, Lilly, and Merck. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue